ea0026p667 | Diabetes therapy | ECE2011
Delhanty P J D
, Huisman M
, van den Berge I
, Abribat T
, Themmen A P N
, van der Lely A J
In Europe more than 50 million adults are diabetic. Of these, 9095% have type 2 diabetes (T2D). It is also recognized that an even larger population is insulin resistant and it is thought that treatment at this early phase of the metabolic syndrome may prevent the occurrence of overt diabetes and associated pathologies. We are in the process of developing unacylated ghrelin (UAG) analogues as therapeutics for T2D. Towards this goal, we have used a mouse protocol in which...